Pharmabranche: Milliardendeal: Eli Lilly kauft Schlafmittel-Firma Centessa
Der US-Pharmakonzern übernimmt Centessa Pharmaceuticals für bis zu 7,8 Milliarden Dollar. Damit erschließt sich Lilly einen neuen Therapiebereich und den…
34,600€
1,47%
Echtzeit-Aktienkurs Centessa Pharmaceuticals PLC (ADRs)
Bid:
Ask:
Nachrichten zur Centessa Pharmaceuticals PLC (ADRs) Aktie
Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash,…
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today…
Centessa Pharmaceuticals (CNTA): Truist sieht 88 % Kurspotenzial - ORX750 bietet Potenzial bei Narkolepsie und idiopathischer Hypersomnie
Das Kernstück in der Pipeline von Centessa Pharmaceuticals (CNTA) bildet das Orexin-Rezeptor-2 (OX2R)-Agonisten-Programm mit den Hauptkandidaten ORX750 und ORX142. ORX750…
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today…
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
Centessa Pharmaceuticals (CNTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company,…
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) –…
Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
…
Centessa Pharmaceuticals announces $150M proposed public offering of American Depositary Shares
…
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company…
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company…
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that…
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company…
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
BOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company…
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company,…
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran
The current therapeutic landscape of hemophilia B in the 7MM is driven by several approved therapies. The hemophilia B market…